

# COMBINATION THERAPY FOR MALIGNANT PERIPHERAL NERVE SHEATH TUMORS

---

[Amin, Neha](#), [Borcherding, Dana](#), [Hirbe, Angela](#)

[Hanford, Charles](#)

T-020000

## Technology Description

Researchers in Angela Hirbe's lab at Washington University have developed a method of treating malignant peripheral nerve sheath tumors (MPNSTs) with a combination of inhibitors. The most effective therapy is to combine an inhibitor of TYK2 with a MEK inhibitor.

MPNSTs are often associated with Neurofibromatosis Type 1 or as a secondary complication of radiation therapy. Despite multiple therapeutic options, 50% of patients see a recurrence.

## Stage of Research

The researchers have tested the combination of TYK2 and MEK inhibitors on MPNST cells *in vitro* and on an NF1 model *in vivo*.

## Applications

- Malignant peripheral nerve sheath tumors (MPNSTs)

## Key Advantages

- Increases response to MEK inhibitor

**Patents:** Pending

**Related Web Links:** Hirbe [Profile](#) & [Lab](#)